Thomas Gremmel1, Endri Xhelili2, Sabine Steiner2, Renate Koppensteiner2, Christoph W Kopp2, Simon Panzer3. 1. Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria. Electronic address: thomas.gremmel@meduniwien.ac.at. 2. Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria. 3. Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
Abstract
BACKGROUND: The long-term prognosis of patients with peripheral arterial disease (PAD) is significantly worse than the prognosis of coronary artery disease (CAD) patients. Detrimental platelet activation could contribute to the increased rate of adverse cardiovascular events in PAD. We therefore investigated whether response to antiplatelet therapy and thrombin inducible platelet activation differ between patients with best medical therapy undergoing angioplasty and stenting for symptomatic PAD (n = 166) or CAD (n = 104). METHODS: Adenosine diphosphate (ADP), arachidonic acid (AA) and thrombin receptor activating peptide (TRAP)-6 inducible platelet reactivity was measured by multiple electrode aggregometry (MEA). Platelet surface expression of P-selectin and activated glycoprotein IIb/IIIa (GPIIb/IIIa) in response to ADP, AA, and TRAP-6, and the formation of monocyte-platelet aggregates (MPA) in response to ADP and TRAP-6 were assessed by flow cytometry. RESULTS: Patients with PAD had significantly higher platelet reactivity in response to ADP and AA by MEA compared to CAD patients. Likewise, the expression of P-selectin and GPIIb/IIIa following stimulation with ADP and AA, and MPA formation in response to ADP were significantly higher in PAD patients than in CAD patients. In response to TRAP-6, patients with PAD showed a significantly increased platelet aggregation by MEA, higher expression of activated GPIIb/IIIa, and more pronounced formation of MPA than CAD patients. CONCLUSION: Following angioplasty and stenting, PAD patients exhibit a significantly diminished response to dual antiplatelet therapy and an increased susceptibility to TRAP-6 inducible platelet activation compared to CAD patients.
BACKGROUND: The long-term prognosis of patients with peripheral arterial disease (PAD) is significantly worse than the prognosis of coronary artery disease (CAD) patients. Detrimental platelet activation could contribute to the increased rate of adverse cardiovascular events in PAD. We therefore investigated whether response to antiplatelet therapy and thrombin inducible platelet activation differ between patients with best medical therapy undergoing angioplasty and stenting for symptomatic PAD (n = 166) or CAD (n = 104). METHODS:Adenosine diphosphate (ADP), arachidonic acid (AA) and thrombin receptor activating peptide (TRAP)-6 inducible platelet reactivity was measured by multiple electrode aggregometry (MEA). Platelet surface expression of P-selectin and activated glycoprotein IIb/IIIa (GPIIb/IIIa) in response to ADP, AA, and TRAP-6, and the formation of monocyte-platelet aggregates (MPA) in response to ADP and TRAP-6 were assessed by flow cytometry. RESULTS:Patients with PAD had significantly higher platelet reactivity in response to ADP and AA by MEA compared to CAD patients. Likewise, the expression of P-selectin and GPIIb/IIIa following stimulation with ADP and AA, and MPA formation in response to ADP were significantly higher in PAD patients than in CAD patients. In response to TRAP-6, patients with PAD showed a significantly increased platelet aggregation by MEA, higher expression of activated GPIIb/IIIa, and more pronounced formation of MPA than CAD patients. CONCLUSION: Following angioplasty and stenting, PAD patients exhibit a significantly diminished response to dual antiplatelet therapy and an increased susceptibility to TRAP-6 inducible platelet activation compared to CAD patients.
Authors: Stefan Stojkovic; Svitlana Demyanets; Christoph W Kopp; Christian Hengstenberg; Johann Wojta; Beate Eichelberger; Simon Panzer; Thomas Gremmel Journal: Front Cardiovasc Med Date: 2020-12-22
Authors: Kerstin Jurk; Korbinian F Rothenaicher; Kathrin Groß; Heidi Rossmann; Gerhard Weißer; Irene Schmidtmann; Thomas Münzel; Christine Espinola-Klein Journal: Front Cardiovasc Med Date: 2022-05-06
Authors: Anne Yaël Nossent; Neda Ektefaie; Johann Wojta; Beate Eichelberger; Christoph Kopp; Simon Panzer; Thomas Gremmel Journal: Int J Mol Sci Date: 2019-11-27 Impact factor: 5.923
Authors: Svitlana Demyanets; Stefan Stojkovic; Lisa-Marie Mauracher; Christoph W Kopp; Johann Wojta; Johannes Thaler; Simon Panzer; Thomas Gremmel Journal: J Clin Med Date: 2020-01-22 Impact factor: 4.241